Proviron
Also known as: Mesterolone
DHT Derivative | Mood, Libido & Muscle Hardening
Overview
Proviron (mesterolone) is an orally active dihydrotestosterone (DHT) derivative that has been used in clinical medicine since the 1960s, primarily in Europe and other international markets. Unlike most oral anabolic steroids, Proviron is not 17-alpha alkylated, which gives it a remarkably low hepatotoxicity profile. It was originally developed for the treatment of androgen deficiency, male infertility (at low doses it can improve sperm quality without fully suppressing the HPT axis), and mood disturbances related to low androgen status. Proviron is approved in numerous countries outside the United States including Germany, the UK, and several countries across Asia, South America, and the Middle East. Its most distinctive pharmacological property is its exceptionally strong binding affinity for sex hormone-binding globulin (SHBG), which effectively displaces testosterone from SHBG and increases the proportion of circulating free testosterone. This mechanism makes Proviron a popular adjunct to testosterone replacement therapy and performance enhancement protocols, where it amplifies the biological activity of co-administered testosterone without meaningfully increasing total androgen load. Proviron is also valued for its anti-estrogenic properties — as a DHT derivative, it cannot aromatize to estrogen, and it competes with testosterone for the aromatase enzyme, reducing overall estrogen conversion. Users consistently report improvements in mood, libido, confidence, and a general sense of well-being, along with a harder, drier, and more defined physical appearance.
Key benefits
- Strong SHBG binding frees more circulating testosterone, enhancing TRT efficacy
- Improved mood, motivation, confidence, and overall sense of well-being
- Significant enhancement of libido and sexual function
- Anti-estrogenic effect reduces the need for dedicated aromatase inhibitors
- Harder, drier, more defined physical appearance without water retention
- Minimal hepatotoxicity due to absence of 17-alpha alkylation
- May improve sperm quality at low doses in subfertile men
- Rapid onset of subjective well-being effects (often within days)
Mechanism of action
Proviron exerts its effects primarily through direct binding to the androgen receptor (AR) as a potent DHT analogue. However, its most therapeutically relevant mechanism is its exceptionally high binding affinity for sex hormone-binding globulin (SHBG). By occupying SHBG binding sites, Proviron displaces testosterone that would otherwise be bound and biologically inactive, effectively increasing free testosterone levels without requiring additional exogenous testosterone. This SHBG-displacement mechanism is the primary reason Proviron is considered synergistic with testosterone — it amplifies the effective androgenic signal from a given dose of testosterone. Proviron also acts as a mild aromatase inhibitor. Because it is a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, and it competes with aromatizable androgens (like testosterone) for access to aromatase, reducing the overall rate of estrogen conversion. This dual mechanism — increasing free testosterone while reducing estrogen — produces the characteristic effects of improved mood, enhanced libido, and the harder, drier physique that Proviron is known for. In muscle tissue, Proviron's anabolic effects are limited because it is rapidly inactivated by 3-alpha hydroxysteroid dehydrogenase, similar to DHT itself. This enzyme is highly expressed in skeletal muscle, which is why Proviron is not considered a significant muscle-building agent on its own but rather an enhancer of other androgens.
Molecular data
- Type
- DHT derivative (C20H32O2)
- Half-life
- ~12 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Sexual Health
Neurological / Mood
Body Composition
Endocrine / Hormonal
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 25 mg/day | Once daily | — |
| — | 50 mg/day | 25 mg twice daily (morning and evening) | — |
| — | 75 mg/day | 25 mg three times daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Accelerated hair thinning or loss in those predisposed to male pattern baldness (DHT-mediated)
- Mild suppression of endogenous testosterone at higher doses (though less suppressive than most AAS)
- Oily skin and increased sebum production
- Mild HDL cholesterol suppression with extended use
- Increased body hair growth
Rare side effects
- Prostate enlargement or aggravation of existing benign prostatic hyperplasia (BPH)
- Priapism (prolonged painful erection) — extremely rare but documented
- Mood changes including increased aggression or irritability at higher doses
- Headaches
- Gastrointestinal discomfort
Contraindications
- Prostate cancer (active or history of androgen-sensitive prostate cancer)
- Severe liver impairment (though hepatotoxicity risk is minimal)
- Breast cancer in males
- Hypersensitivity to mesterolone or any excipients
- Women who are pregnant or may become pregnant (androgenic effects on fetus)
Monitoring
- PSA and digital rectal exam: baseline and periodically, especially in men over 40
- Lipid panel (HDL/LDL): baseline and every 3-6 months during use
- Free and total testosterone, SHBG: to assess the SHBG-displacement effect
- Estradiol (sensitive assay): to gauge anti-estrogenic impact and avoid over-suppression
- Liver function tests: baseline and periodically, though significant elevation is uncommon
References
Primary literature and clinical-trial data informing this entry.